AR044496A1 - N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND ITS EMPLOYMENT AS MEDICATIONS - Google Patents

N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND ITS EMPLOYMENT AS MEDICATIONS

Info

Publication number
AR044496A1
AR044496A1 ARP040100469A ARP040100469A AR044496A1 AR 044496 A1 AR044496 A1 AR 044496A1 AR P040100469 A ARP040100469 A AR P040100469A AR P040100469 A ARP040100469 A AR P040100469A AR 044496 A1 AR044496 A1 AR 044496A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
mean
links
aryl
Prior art date
Application number
ARP040100469A
Other languages
Spanish (es)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32841665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044496(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR044496A1 publication Critical patent/AR044496A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

N-arilheterociclos substituidos, sus sales fisiológicamente tolerables y derivados fisiológicamente funcionales. Los compuestos son útiles como aneroxígenos. Reivindicación 1: Un compuesto de fórmula (1) en la cual R1, R2 significan de manera independiente H, alquilo C1-8, -(CR78R79)o-R12, alcoxi C1-4-alquilo C1-4, ariloxi-alquilo C1-4, alquenilo C3-8, alquinilo C3-8, CO-alquilo C1-8, -CO-(CH2)o-R12, CO-ariloxi-alquilo C1-4, CO-alquenilo C2-8, CO-alquinilo C2-8, COCH-CH(R13), COCC(R14), CO-alquil C1-4-S(O)p-alquilo C1-4, CO(C(R15)(R16))qN(R17)(R18), CO(C(R19)(R20))rCON(R21)(R22) o CO(C(R23)(R24))sO(R25); o bien R1 y R2, forman junto con el átomo de nitrógeno al cual están unidos, un anillo mono-, bi- o espirocíclico de 4 a 10 eslabones que además del átomo de nitrógeno, puede contener o a 4 heteroátomos adicionales seleccionados del grupo de oxígeno, nitrógeno y azufre, pudiendo el sistema anular heterocíclico estar substituido adicionalmente con F, Cl, Br, CF3, NO2, CN, alquilo C1-6, O-alquilo C1-8, alcoxi C1-4-alquilo C1-4, hidroxi-alquilo C1-4, alquilen C0-8-arilo, oxo, CO(R26), CON(R27)(R28), hidroxi, COO(R29), N(R30)COalquilo C1-6, N(R31)(R32) o SO2CH3; o vale 0, 1, 2, 3, 4, 5 ó 6; p vale 0, 1 ó 2; q, r, s valen de manera independiente 0, 1, 2, 3 ó 4; R13, R14 significan de manera independiente entre sí, un sistema anular aromático de 5 a 10 eslabones, que puede contener 0-2 heteroátomos adicionales del grupo de nitrógeno, oxígeno y azufre, y que puede estar substituido con F, Cl, Br, CF3, NO2, CN, alquilo C1-6 o O-alquilo C1-8; R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32 significan de manera independiente entre sí H o alquilo C1-6; R18 significa H, alquilo C1-6, COalquilo C1-6 o CO(R33); o bien R17 y R18, R21 y R22, R27 y R28, y R31 y R32, significan de manera independiente entre sí, y opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre; R33 significa un sistema anular aromático de 5-10 eslabones, que puede contener 0-2 heteroátomos adicionales del grupo de nitrógeno, oxígeno y azufre, y que puede estar substituido con F, Cl, Br, CF3, NO2, CN, alquilo C1-6 o O-alquilo C1-8; R12 significa OH, O-alquilo C1-6, Oalquilen C0-8-arilo, CN, S-alquilo C1-6, COO(R80), CON(R81)(R93), N(R82)(R83) o anillo mono-, bi- o espirocíclico de 3-12 eslabones, que puede contener uno o varios heteroátomos del grupo de N, O y S, y el anillo de 3-12 eslabones puede contener substituyentes adicionales tales como F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-alquilo C1-6, alcoxi C1-4-alquilo C1-4, S-alquilo C1-6, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, O-cicloalquilo C3-8, cicloalquenilo C3-8, O-cicloalquenilo C3-8, alquinilo C2-6, O-alquilen C0-8-arilo, N(R34)(R35), COCH-CH(R36), (C(R37)(R38))t(R39), CO(C(R37)(R38))t(R39), COalquilo C1-6, COCOOalquilo C1-6, COO(R40), S(O)u(R41) o COOH; t vale 0, 1, 2, 3, 4, 5 ó 6; u vale 0, 1 ó 2; o bien R34, R35, R37, R38 significan de manera independiente entre sí H o alquilo C1-8; R34 y R35, significan opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre, y opcionalmente puede estar substituido con 1 o 2 grupos oxo; R36, R39 significan de manera independiente entre sí cicloalquilo C3-8, un sistema anular aromático de 5-10 eslabones, que puede contener 0-2 heteroátomos adicionales del grupo de nitrógeno, oxígeno y azufre, y que puede estar substituido con F, Cl, Br, CF3, NO2, CN, alquilo C1-6 o O-alquilo C1-8; R40 significa H, alquilo C1-8, alquenilo C2-6 o alquilen C0-8-arilo; R41 significa alquilo C1-8, un sistema anular aromático de 5-10 eslabones, que puede contener 0-2 heteroátomos adicionales del grupo de nitrógeno, oxígeno y azufre, y que puede estar substituido con F, Cl, Br, CF3, NO2, CN, alquilo C1-6 o O-alquilo C1-8; R78, R79 significan de manera independiente entre sí H, alquilo C1-8, hidroxi-alquilo C1-4, OH o alcoxi C1-4-alquilo C1-4; R80, R81, R93 significan de manera independiente entre sí alquilo C1-8, alquenilo C2-6, alquilen C0-8-arilo; R82, R83 significan de manera independiente entre sí H o alquilo C1-6; o bien R82 y R83, significan, opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre, y opcionalmente puede estar substituido con 1 o 2 grupos oxo; R3 significa H, alquilo C1-6; R4, R5 significan, de manera independiente entre sí H, alquilo C1-6, OH, O-alquilo C1-6, O-COalquilo C1-6 o S-alquilo C1-6; o bien R6, R7, R8, R9 significan de manera independiente entre sí H o alquilo C1-8; o bien R6 y R7, y R8 y R9, significan de manera independiente entre sí y opcionalmente, oxo; n, m valen de manera independiente entre sí 0, 1 o 2; A, B, D, G significan de manera independiente entre sí N o C(R42); o bien los grupos A y B, o los grupos D y G son en cada caso C(R42) y forman juntos un radical carbocíclico o heterocíclico de 5 o 6 eslabones, de manera tal que se origina en conjunto un sistema bicíclico; R42 significa H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alquilo C1-6, O-alcoxi C1-4-alquilo C1-4, S-alquilo C1-6, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, O-cicloalquilo C3-8, cicloalquenilo C3-8, O-cicloalquenilo C3-8, alquinilo C2-6, alquilenC0-8-arilo, O-alquilen C0-8-arilo, S-arilo, N(R43)(R44), SO2-CH3, COOH, COO-alquilo C1-6, CON(R45)(R46), N(R47)CO(R48), N(R49)SO2(R50), CO(R51), -(CR84R85)x-O(R86); R43, R44, R45, R46, R47, R49 significan de manera independiente entre sí H o alquilo C1-8; o bien R43 y R44, y R45 y R46, significan de manera independiente entre sí y opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre; R48, R50, R51 significan de manera independiente entre sí H, alquilo C1-8 o arilo; R84, R85 significan de manera independiente entre sí H o alquilo C1-8; R86 significa H, alquilo C1-6 o arilo; x vale 1, 2, 3, 4, 5 ó 6; R10 significa H, alquilo C1-8, alquenilo C3-6 o alquinilo C3-6; X significa N(R52), O, un enlace, C=C, C(R53)(R54), C(R55)(R56)O, CO, C:::C, o un grupo de fórmula -(CR87R88)y-, en la cual uno o más grupos -(CR87R88)- pueden haber sido reemplazados por Y, originándose un radical químicamente con sentido; Y significa O, S o N(R89); R52, R53, R54, R55, R56 significan, de manera independiente entre sí H o alquilo C1-8; R87, R88 significan de manera independiente entre sí H o alquilo C1-4, pudiendo tener R87 y R88 en los grupos "y", en cada caso, los mismos significados o significados diferentes; y vale 2, 3, 4, 5 ó 6; E significa una estructura anular carbo- o heterocíclica, bivalente de 3 a 14 eslabones, y con 0 a 4 heteroátomos del grupo de N, O y S, que opcionalmente puede portar substituyentes del grupo de H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-alquilo C1-6, O-alcoxi C1-4-alquilo C1-4, S-alquilo C1-6, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, O-cicloalquilo C3-8, cicloalquenilo C3-8, O-cicloalquenilo C3-8, alquinilo C2-6, alquilen C0-8-arilo, O-alquilen C0-8-arilo, S-arilo, N(R57)(R58), SO2-CH3, COOH, COO-alquilo C1-6, CON(R59)(R60), N(R61)CO(R62), N(R63)SO2(R64), CO(R65) y que puede ser mono- o bicíclica; R57, R58, R59, R60, R61, R63 significan de manera independiente entre sí H o alquilo C1-8; o bien R57 y R58, y R59 y R60, significan de manera independiente entre sí y opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre; R62, R64, R65 significan de manera independiente entre sí H, alquilo C1-8, arilo; K significa un enlace, O, OCH2, CH2O, S, SO, SO2, N(R66), N(R67)CO, CON(R68), (C(R69)(R70))v, CO, C:::C, C=C un grupo de fórmula -(CR90R91)z-, en donde uno o varios grupos -(CR90R91)- pueden haber sido reemplazados por Z, originándose un radical químicamente con sentido; v vale 1, 2, 3 ó 4; R66, R67, R68, R69, R70 significan de manera independiente entre sí H o alquilo C1-8; Z significa O, S, N(R92), CO, SO o SO2; R90, R91 significan de manera independiente entre sí H, alquilo C1-8, hidroxi-alquilo C1-4, hidroxi, alcoxi C1-4-alquilo C1-4, y pudiendo tener R90 y R91 en los grupos "z" en cada caso los mismos significados o significados diferentes; z vale 2, 3, 4, 5 ó 6; R92 significa H o alquilo C1-8; R11 significa H, alquilo C1-8, alcoxi C1-4-alquilo C1-4, alquenilo C3-8, alquinilo C3-8, un anillo mono-, bi-, tri- o espirocíclico, de 3 a 10 eslabones que puede contener 1, 2, 3 o 4 heteroátomos seleccionados del grupo de oxígeno, nitrógeno y azufre, pudiendo estar el sistema anular substituido adicionalmente con F, Cl, Br, CF3, NO2, CN, alquilo, O-alquilo C1-8, alcoxi C1-4-alquilo C1-4, alquilen C0-8-arilo, oxo, CO(R71), CON(R72)(R73), hidroxi, hidroxi-alquilo C1-4, COO(R74), N(R75)COalquilo C1-6, N(R76)(R77), SO2CH3 o SCF3; R71, R72, R73, R74, R75, R76, R77 significan de manera independiente entre sí y opcionalmente junto con el átomo de nitrógeno al cual al cual están unidos, un anillo de 5-6 eslabones que, además del átomo de nitrógeno, puede contener aún 0-1 heteroátomos adicionales del grupo de N-alquilo C1-6, oxígeno y azufre; o bien E, K y R11 forman juntos un triciclo, pudiendo ser los anillos, de manera independiente entre sí, saturados, parcialmente saturados o insaturados, y pudiendo contener en cada caso 3-8 átomos en el anillo; sus N-óxidos y sus sales fisiológicamente tolerables.N-substituted arylheterocycles, their physiologically tolerable salts and physiologically functional derivatives. The compounds are useful as anaerogens. Claim 1: A compound of formula (1) in which R1, R2 independently mean H, C1-8 alkyl, - (CR78R79) or-R12, C1-4 alkoxy-C1-4 alkyl, aryloxy-C1-alkyl 4, C3-8 alkenyl, C3-8 alkynyl, CO- C1-8 alkyl, -CO- (CH2) or -R12, CO-aryloxy-C1-4 alkyl, CO-C2-8 alkenyl, CO-C2 alkynyl 8, COCH-CH (R13), COCC (R14), CO-C 1-4 alkyl-S (O) p-C 1-4 alkyl, CO (C (R15) (R16)) qN (R17) (R18), CO (C (R19) (R20)) rCON (R21) (R22) or CO (C (R23) (R24)) sO (R25); or R1 and R2 together with the nitrogen atom to which they are attached, a mono-, bi- or spirocyclic ring of 4 to 10 links which, in addition to the nitrogen atom, may contain or 4 additional heteroatoms selected from the oxygen group , nitrogen and sulfur, the heterocyclic ring system being able to be additionally substituted with F, Cl, Br, CF3, NO2, CN, C1-6 alkyl, O-C1-8 alkyl, C1-4 alkoxy-C1-4 alkyl, hydroxy- C1-4 alkyl, C0-8-aryl alkylene, oxo, CO (R26), CON (R27) (R28), hydroxy, COO (R29), N (R30) C1-6 alkyl, N (R31) (R32) or SO2CH3; or is worth 0, 1, 2, 3, 4, 5 or 6; p is worth 0, 1 or 2; q, r, s are worth 0, 1, 2, 3 or 4 independently; R13, R14 independently mean to each other, an aromatic ring system of 5 to 10 links, which may contain 0-2 additional heteroatoms of the nitrogen, oxygen and sulfur group, and which may be substituted with F, Cl, Br, CF3 , NO2, CN, C1-6 alkyl or O-C1-8 alkyl; R15, R16, R17, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32 independently mean each other H or C1-6 alkyl; R18 means H, C1-6 alkyl, CO C1-6 alkyl or CO (R33); or R17 and R18, R21 and R22, R27 and R28, and R31 and R32, mean independently of each other, and optionally together with the nitrogen atom to which they are attached, a ring of 5-6 links that, in addition to the nitrogen atom, it may still contain 0-1 additional heteroatoms of the N- C1-6 alkyl, oxygen and sulfur group; R33 means an aromatic ring system of 5-10 links, which may contain 0-2 additional hetero atoms of the nitrogen, oxygen and sulfur group, and which may be substituted with F, Cl, Br, CF3, NO2, CN, C1- alkyl 6 or O-C1-8 alkyl; R12 means OH, O-C1-6 alkyl, C0-8-alkyl aryl, CN, S-C1-6 alkyl, COO (R80), CON (R81) (R93), N (R82) (R83) or mono ring -, bi- or spirocyclic of 3-12 links, which may contain one or more heteroatoms of the group of N, O and S, and the 3-12 link ring may contain additional substituents such as F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-C1-6 alkyl, C1-4 alkoxy-C1-4 alkyl, S-C1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl , C3-8 O-cycloalkyl, C3-8 cycloalkenyl, C3-8 O-cycloalkenyl, C2-6 alkynyl, C0-8 -alkyl-aryl, N (R34) (R35), COCH-CH (R36), ( C (R37) (R38)) t (R39), CO (C (R37) (R38)) t (R39), CO C1-6 alkyl, COCOO C1-6 alkyl, COO (R40), S (O) or (R41 ) or COOH; t is worth 0, 1, 2, 3, 4, 5 or 6; u is worth 0, 1 or 2; or R34, R35, R37, R38 independently mean each other H or C1-8 alkyl; R34 and R35, optionally mean together with the nitrogen atom to which they are attached, a ring of 5-6 links which, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the N-C1-C-alkyl group 6, oxygen and sulfur, and may optionally be substituted with 1 or 2 oxo groups; R36, R39 independently mean C3-8 cycloalkyl, an aromatic ring system of 5-10 links, which may contain 0-2 additional heteroatoms of the nitrogen, oxygen and sulfur group, and which may be substituted with F, Cl , Br, CF3, NO2, CN, C1-6 alkyl or O-C1-8 alkyl; R40 means H, C1-8 alkyl, C2-6 alkenyl or C0-8-aryl alkylene; R41 means C1-8 alkyl, an aromatic ring system of 5-10 links, which may contain 0-2 additional hetero atoms of the nitrogen, oxygen and sulfur group, and which may be substituted with F, Cl, Br, CF3, NO2, CN, C1-6 alkyl or O-C1-8 alkyl; R78, R79 independently mean each other H, C1-8 alkyl, hydroxy-C1-4 alkyl, OH or C1-4 alkoxy-C1-4 alkyl; R80, R81, R93 independently mean each other C1-8 alkyl, C2-6 alkenyl, C0-8-aryl alkylene; R82, R83 independently mean each other H or C1-6 alkyl; or R82 and R83, optionally, together with the nitrogen atom to which they are attached, a ring of 5-6 links which, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the group of N- C1-6 alkyl, oxygen and sulfur, and may optionally be substituted with 1 or 2 oxo groups; R3 means H, C1-6 alkyl; R4, R5 independently mean H, C1-6 alkyl, OH, O-C1-6 alkyl, O-CO C1-6 alkyl or S-C1-6 alkyl; or R6, R7, R8, R9 independently mean H or C1-8 alkyl; or R6 and R7, and R8 and R9, mean independently of each other and optionally, oxo; n, m are worth 0, 1 or 2 independently of each other; A, B, D, G independently mean each other N or C (R42); Either groups A and B, or groups D and G are in each case C (R42) and together form a carbocyclic or heterocyclic radical of 5 or 6 links, so that a bicyclic system originates together; R42 means H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-C1-6 alkyl, O-C1-4 alkoxy-C1-4 alkyl, S-C1-6 alkyl, C1 alkyl -6, C2-6 alkenyl, C3-8 cycloalkyl, O3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 O-cycloalkenyl, C2-6 alkynyl, C0-8-aryl, O-C0-8 alkylene aryl, S-aryl, N (R43) (R44), SO2-CH3, COOH, COO-C1-6 alkyl, CON (R45) (R46), N (R47) CO (R48), N (R49) SO2 ( R50), CO (R51), - (CR84R85) xO (R86); R43, R44, R45, R46, R47, R49 independently mean each other H or C1-8 alkyl; or R43 and R44, and R45 and R46, mean independently of each other and optionally together with the nitrogen atom to which they are attached, a ring of 5-6 links that, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the N-C1-6 alkyl, oxygen and sulfur group; R48, R50, R51 independently mean each other H, C1-8 alkyl or aryl; R84, R85 independently mean each other H or C1-8 alkyl; R86 means H, C1-6 alkyl or aryl; x is worth 1, 2, 3, 4, 5 or 6; R10 means H, C1-8 alkyl, C3-6 alkenyl or C3-6 alkynyl; X means N (R52), O, a bond, C = C, C (R53) (R54), C (R55) (R56) O, CO, C ::: C, or a group of formula - (CR87R88) and-, in which one or more groups - (CR87R88) - may have been replaced by Y, originating a chemically meaningful radical; Y means O, S or N (R89); R52, R53, R54, R55, R56 means, independently of each other H or C1-8 alkyl; R87, R88 independently mean each other H or C1-4 alkyl, and R87 and R88 may have in the groups "and", in each case, the same different meanings or meanings; and is worth 2, 3, 4, 5 or 6; E means a carbo- or heterocyclic ring structure, bivalent from 3 to 14 links, and with 0 to 4 heteroatoms of the group of N, O and S, which may optionally carry substituents of the group of H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, oxo, O-C1-6 alkyl, O-C1-4 alkoxy-C1-4 alkyl, S-C1-6 alkyl, C1-6 alkyl, C2-6 alkenyl, C3 cycloalkyl -8, C3-8 O-cycloalkyl, C3-8 cycloalkenyl, C3-8 O-cycloalkenyl, C2-6 alkynyl, C0-8-aryl alkylene, C0-8-aryl-O-alkylene, S-aryl, N (R57 ) (R58), SO2-CH3, COOH, COO-C1-6 alkyl, CON (R59) (R60), N (R61) CO (R62), N (R63) SO2 (R64), CO (R65) and that it can be mono- or bicyclic; R57, R58, R59, R60, R61, R63 independently mean each other H or C1-8 alkyl; or R57 and R58, and R59 and R60, mean independently of each other and optionally together with the nitrogen atom to which they are attached, a ring of 5-6 links that, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the N-C1-6 alkyl, oxygen and sulfur group; R62, R64, R65 independently mean each other H, C1-8 alkyl, aryl; K means a link, O, OCH2, CH2O, S, SO, SO2, N (R66), N (R67) CO, CON (R68), (C (R69) (R70)) v, CO, C ::: C, C = C a group of formula - (CR90R91) z-, where one or more groups - (CR90R91) - may have been replaced by Z, giving rise to a chemically meaningful radical; v is worth 1, 2, 3 or 4; R66, R67, R68, R69, R70 independently mean each other H or C1-8 alkyl; Z means O, S, N (R92), CO, SO or SO2; R90, R91 independently mean each other H, C1-8 alkyl, hydroxy-C1-4 alkyl, hydroxy, C1-4 alkoxy-C1-4 alkyl, and R90 and R91 may be in groups "z" in each case the same meanings or different meanings; z is worth 2, 3, 4, 5 or 6; R92 means H or C1-8 alkyl; R11 means H, C1-8 alkyl, C1-4 alkoxy-C1-4 alkyl, C3-8 alkenyl, C3-8 alkynyl, a mono-, bi-, tri- or spirocyclic ring, of 3 to 10 links that may contain 1, 2, 3 or 4 heteroatoms selected from the group of oxygen, nitrogen and sulfur, the ring system being able to be additionally substituted with F, Cl, Br, CF3, NO2, CN, alkyl, O-C1-8 alkyl, C1- alkoxy 4-C1-4alkyl, C0-8-aryl alkylene, oxo, CO (R71), CON (R72) (R73), hydroxy, hydroxy-C1-4alkyl, COO (R74), N (R75) C1-Calkyl 6, N (R76) (R77), SO2CH3 or SCF3; R71, R72, R73, R74, R75, R76, R77 mean independently of each other and optionally together with the nitrogen atom to which they are attached, a ring of 5-6 links that, in addition to the nitrogen atom, can still contain 0-1 additional heteroatoms of the N- C1-6 alkyl, oxygen and sulfur group; or E, K and R11 together form a tricycle, the rings may be, independently of one another, saturated, partially saturated or unsaturated, and may in each case contain 3-8 atoms in the ring; their N-oxides and their physiologically tolerable salts.

ARP040100469A 2003-02-14 2004-02-16 N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND ITS EMPLOYMENT AS MEDICATIONS AR044496A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10306250A DE10306250A1 (en) 2003-02-14 2003-02-14 Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
AR044496A1 true AR044496A1 (en) 2005-09-14

Family

ID=32841665

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100469A AR044496A1 (en) 2003-02-14 2004-02-16 N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND ITS EMPLOYMENT AS MEDICATIONS

Country Status (29)

Country Link
EP (1) EP1597228A2 (en)
JP (1) JP2006517563A (en)
KR (1) KR20050101215A (en)
CN (1) CN100506792C (en)
AR (1) AR044496A1 (en)
AU (1) AU2004212145B2 (en)
BR (1) BRPI0407504A (en)
CA (1) CA2516118A1 (en)
CO (1) CO5690548A2 (en)
DE (1) DE10306250A1 (en)
EC (1) ECSP055967A (en)
HR (1) HRP20050710A2 (en)
MA (1) MA27735A1 (en)
MX (1) MXPA05008449A (en)
MY (1) MY139102A (en)
NO (1) NO20054220L (en)
NZ (1) NZ541823A (en)
OA (1) OA13027A (en)
PA (1) PA8595901A1 (en)
PE (1) PE20040952A1 (en)
PL (1) PL378065A1 (en)
RS (1) RS20050666A (en)
RU (1) RU2005128551A (en)
TN (1) TNSN05194A1 (en)
TW (1) TW200510297A (en)
UA (1) UA86760C2 (en)
UY (1) UY28186A1 (en)
WO (1) WO2004072025A2 (en)
ZA (1) ZA200506369B (en)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
EP2251343A1 (en) 2003-05-15 2010-11-17 Arqule, Inc. Imidazothiazoles as p38-kinase-inhibitors
WO2005009988A1 (en) 2003-07-24 2005-02-03 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
PL1867644T3 (en) * 2003-07-24 2009-10-30 Euro Celtique Sa Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
EP2426120A1 (en) 2003-08-18 2012-03-07 Fujifilm Finechemicals Co., Ltd. Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them
DE10360745A1 (en) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg New amide compounds having MCH antagonist activity and medicaments containing these compounds
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004003812A1 (en) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Aryl-substituted heterocycles, methods of their preparation and their use as pharmaceuticals
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
WO2006010082A1 (en) * 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
WO2006022442A1 (en) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. Novel heterocyclic amide derivatives having dihydroorotate dehydrogenase inhibiting activity
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007003321A (en) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents.
CA2582327A1 (en) 2004-10-01 2006-04-13 Takao Suzuki 2-arylcarboxamide-nitrogeneous heterocycle compound
US7868014B2 (en) 2004-10-18 2011-01-11 Eli Lilly And Company 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
DE102004051277A1 (en) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclic carbonyl compounds
JPWO2006054793A1 (en) * 2004-11-19 2008-06-05 財団法人新産業創造研究機構 Benzofuran compound and pharmaceutical composition containing the same
UY29321A1 (en) 2004-12-30 2006-03-31 Janssen Pharmaceutica Nv PIPERAZINILUREAS AND PIPERIDINILUREAS AS AMID HYDROLASSES MODULATORS OF FATTY ACIDS
AU2006208043B2 (en) 2005-01-25 2012-09-20 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
DE602006006463D1 (en) 2005-09-30 2009-06-04 Hoffmann La Roche INDANDERIVATES AS ANTAGONISTS OF THE MCH RECEPTOR
EP1987028A2 (en) 2006-02-10 2008-11-05 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
CN101384605A (en) * 2006-02-15 2009-03-11 塞诺菲-安万特股份有限公司 Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
KR20080095879A (en) * 2006-02-15 2008-10-29 사노피-아벤티스 Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
WO2007123269A1 (en) * 2006-04-19 2007-11-01 Astellas Pharma Inc. Azolecarboxamide derivative
WO2007121484A2 (en) 2006-04-19 2007-10-25 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
UA93548C2 (en) 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
US8461167B2 (en) * 2006-05-08 2013-06-11 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
KR101441365B1 (en) 2006-05-08 2014-09-18 어리어드 파마슈티칼스, 인코포레이티드 Monocyclic heteroaryl compounds
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
CN101506203B (en) * 2006-08-24 2013-10-16 诺瓦提斯公司 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other syndromes
US7691893B2 (en) 2006-09-11 2010-04-06 Glaxo Group Limited Chemical compounds
JP2010504362A (en) * 2006-09-25 2010-02-12 アレテ セラピューティクス， インコーポレイテッド Soluble epoxide hydrolase inhibitor
AR063311A1 (en) * 2006-10-18 2009-01-21 Novartis Ag ORGANIC COMPOUNDS
US7759344B2 (en) * 2007-01-09 2010-07-20 Amgen Inc. Bis-aryl amide derivatives and methods of use
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
RU2470017C2 (en) * 2007-06-08 2012-12-20 Янссен Фармацевтика Н.В. Piperidine/piperazine derivatives
CA2687912C (en) 2007-06-08 2015-11-03 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
JP5464709B2 (en) 2007-06-08 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Piperidine / piperazine derivatives
TWI452044B (en) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp Morpholine derivative
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
BRPI0817101A2 (en) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 1,3-disubstituted 4- (aryl-x-phenyl) -1h-pyridin-2-ones
ATE496906T1 (en) 2007-09-14 2011-02-15 Ortho Mcneil Janssen Pharm 1',3'-DISUBSTITUTED 4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1'H-Ä1,4'ÜBIPYRI INYL-2'-ONE
CN101801930B (en) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
PL2212282T3 (en) * 2007-10-17 2012-02-29 Sanofi Sa Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
PT2215058E (en) * 2007-10-17 2012-03-06 Sanofi Sa Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
PT2205558E (en) * 2007-10-17 2012-11-02 Sanofi Sa Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
PL2212283T3 (en) * 2007-10-17 2012-01-31 Sanofi Sa Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
CA2703106C (en) 2007-10-24 2015-12-01 Astellas Pharma Inc. Azolecarboxamide derivatives as trka inhibitors
WO2009062676A2 (en) 2007-11-14 2009-05-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2070924A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
EP2070916A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
EP2070925A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft New 2-substituted tiazol-4-carboxylic acid derivatives, their manufacture and use as medicine
RU2364597C1 (en) 2007-12-14 2009-08-20 Андрей Александрович Иващенко HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM
JP5579170B2 (en) * 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pharmaceutical combination comprising a DGAT inhibitor and a PPAR agonist
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010033349A1 (en) * 2008-09-16 2010-03-25 Merck & Co., Inc. Phthalimide derivative metabotropic glutamate r4 ligands
JP2012006837A (en) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd 2-indoleacrylamide analogue
RU2517181C2 (en) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Indole and benzomorpholine derivatives as modulator of metabotropic glutamate receptors
AU2009314631B2 (en) 2008-11-12 2014-07-31 Takeda Pharmaceutical Company Limited Pyrazinopyrazines and derivatives as kinase inhibitors
BRPI0921333A2 (en) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa indole and benzoxazine derivatives as metabotropic glutamate receptor modulators
AR074466A1 (en) * 2008-12-05 2011-01-19 Sanofi Aventis PIPERIDINE ESPIRO PIRROLIDINONA AND PIPERIDINONA REPLACED AND ITS THERAPEUTIC USE IN DISEASES MEDIATED BY THE MODULATION OF H3 RECEPTORS.
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2010101247A1 (en) 2009-03-05 2010-09-10 塩野義製薬株式会社 Cyclohexane derivative having npy y5 receptor antagonism
US8889674B2 (en) 2009-03-05 2014-11-18 Shionogi & Co., Ltd. Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
BRPI1010831A2 (en) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa 1,2,4-triazolo [4,3-a] pyridine derivatives and their as positive allosteric modulators of mglur2 receptors
KR101753826B1 (en) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2011060026A1 (en) 2009-11-12 2011-05-19 Jansen Pharmaceutica Nv Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
UA108233C2 (en) 2010-05-03 2015-04-10 Fatty acid amide hydrolysis activity modulators
WO2011143162A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
WO2011143150A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
EP2569304A1 (en) * 2010-05-11 2013-03-20 Sanofi Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
UY33469A (en) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING ROAD
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JP5852666B2 (en) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
PT2649069E (en) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2683700B1 (en) 2011-03-08 2015-02-18 Sanofi Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012170561A1 (en) * 2011-06-06 2012-12-13 The Scripps Research Institute (T.S.R.I.) N-benzylindole modulators of pparg
US8957093B2 (en) 2011-06-06 2015-02-17 The Scripps Research Institute N-biphenylmethylindole modulators of PPARG
WO2013078240A1 (en) 2011-11-22 2013-05-30 Ripka Amy S N-biphenylmethylbenzimidazole modulators of pparg
WO2013085954A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
WO2013085957A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors
CA2873075A1 (en) * 2012-05-11 2013-07-14 Abbvie Inc. Nampt inhibitors
US9499539B2 (en) 2012-11-05 2016-11-22 Nantbioscience, Inc. Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
AR094929A1 (en) 2013-02-28 2015-09-09 Bristol Myers Squibb Co DERIVATIVES OF PHENYLPIRAZOL AS POWERFUL INHIBITORS OF ROCK1 AND ROCK2
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN109999025A (en) 2014-01-21 2019-07-12 詹森药业有限公司 Positive allosteric modulator or the combination of normotopia agonist including metabotropic glutamate energy receptor subtype 2 and application thereof
NZ722385A (en) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US10016394B2 (en) 2014-04-16 2018-07-10 The Scripps Research Institute PPARG modulators for treatment of osteoporosis
MX2017000613A (en) * 2014-07-16 2017-04-27 Novogen ltd Functionalised and substituted indoles as anti-cancer agents.
EP3183248B1 (en) * 2014-08-21 2020-11-11 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
JP2017526706A (en) * 2014-09-10 2017-09-14 エピザイム，インコーポレイティド Isoxazole carboxamide compounds
KR20180044384A (en) * 2015-08-28 2018-05-02 그렌마크 파머수티칼스 에스. 아. As a ROR gamma modulator, novel carbocyclic compounds
SI3430010T1 (en) 2016-03-17 2020-10-30 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
CN108815167B (en) * 2017-05-24 2021-04-13 四川晶华生物科技有限公司 Application of compound in preparing medicine for treating tumor
TW202136238A (en) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 ROR[gamma]T inhibitor, preparation method therefor and use thereof
CN115160269A (en) * 2021-04-02 2022-10-11 北京大学 Arylcarboxamide derivatives as positive allosteric modulators of NMDAR

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (en) 1990-06-18 1992-09-04 Adir NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
EP0788498B1 (en) * 1994-10-26 2001-08-16 PHARMACIA & UPJOHN COMPANY Phenyloxazolidinone antimicrobials
PL327938A1 (en) 1996-01-17 1999-01-04 Novo Nordisk As Derivatives of 1,2,4-thiadiazine and 1,4-thiazine, their production and application
CZ300837B6 (en) 1996-08-30 2009-08-26 Novo Nordisk A/S GLP-1 (7-37) derivatives or analogs thereof, pharmaceutical composition in which the derivatives are comprised as well as their use
PT958296E (en) 1996-12-31 2003-11-28 Reddys Lab Ltd Dr HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND ITS UTILIZATION IN THE TREATMENT OF RELATED DIABETES AND DISEASES
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
HUP0003999A3 (en) 1997-07-16 2003-03-28 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them
CO4970713A1 (en) 1997-09-19 2000-11-07 Sanofi Synthelabo DERIVATIVES OF CARBOXAMIDOTIAZOLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AU1296899A (en) * 1997-11-07 1999-05-31 Schering Corporation Phenyl-alkyl-imidazoles as h3 receptor antagonists
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (en) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Aryl-substituted propanolamine derivatives and their use
WO2000035454A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AU2460600A (en) * 1999-02-10 2000-08-29 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
PL350907A1 (en) * 1999-04-09 2003-02-10 Astrazeneca Ab Adamantane derivatives
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
SE9901875D0 (en) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
JP2003502369A (en) 1999-06-18 2003-01-21 メルク エンド カムパニー インコーポレーテッド Arylthiazolidinedione derivatives and aryloxazolidinedione derivatives
MXPA02000973A (en) 1999-07-29 2002-07-30 Lilly Co Eli Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists.
CN1372541A (en) 1999-09-01 2002-10-02 阿文蒂斯药物德国有限公司 Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
ES2287120T3 (en) 2000-04-28 2007-12-16 Asahi Kasei Pharma Corporation NEW BICYCLE COMPOUNDS.
DE60115227T2 (en) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. TETRAHYDROISOCHINOLINE ANALOGUE AS GROWTH HORMONE SECRETAGOGA
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc Melanocortin receptor agonists
RU2292345C9 (en) * 2000-07-17 2007-05-10 Ранбакси Лабораторис Лимитед Oxazolidinone derivatives
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
MXPA03000923A (en) * 2000-07-31 2003-06-09 Smithkline Beecham Plc Carboxamide compounds and their use as antagonists of a human 11cby receptor.
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Biphenylcarboxamides useful as lipid lowering agents
JP2002338537A (en) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp Amide compound and its medicinal use
WO2002098839A1 (en) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides and process for preparation thereof
WO2002098871A1 (en) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Phenylcarboxamides and process for preparation thereof
AU2002346048A1 (en) * 2001-06-07 2002-12-16 Merck And Co., Inc. Benzodiazepine bradykinin antagonists
DE10142734A1 (en) 2001-08-31 2003-03-27 Aventis Pharma Gmbh New (((oxazolylalkyl)-cycloalkyl)-alkyl)-benzoic acid derivatives, are peroxisome proliferator activated receptor agonists or antagonists used e.g. for treating lipid metabolism disorders, type II diabetes, syndrome X and obesity
AU2003227437A1 (en) * 2002-04-23 2003-11-10 Shionogi And Co., Ltd. PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
JP2004175739A (en) * 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd Medicinal composition

Also Published As

Publication number Publication date
MXPA05008449A (en) 2006-05-25
UY28186A1 (en) 2004-09-30
NO20054220D0 (en) 2005-09-12
CA2516118A1 (en) 2004-08-26
PA8595901A1 (en) 2004-09-16
RU2005128551A (en) 2006-02-10
TNSN05194A1 (en) 2007-06-11
HRP20050710A2 (en) 2006-07-31
WO2004072025A3 (en) 2004-12-23
DE10306250A1 (en) 2004-09-09
NO20054220L (en) 2005-10-28
CO5690548A2 (en) 2006-10-31
PE20040952A1 (en) 2005-02-08
NZ541823A (en) 2009-01-31
EP1597228A2 (en) 2005-11-23
ZA200506369B (en) 2006-07-26
AU2004212145B2 (en) 2010-06-17
AU2004212145A1 (en) 2004-08-26
ECSP055967A (en) 2006-01-16
TW200510297A (en) 2005-03-16
MA27735A1 (en) 2006-02-01
CN100506792C (en) 2009-07-01
UA86760C2 (en) 2009-05-25
JP2006517563A (en) 2006-07-27
OA13027A (en) 2006-11-10
BRPI0407504A (en) 2006-02-14
PL378065A1 (en) 2006-02-20
RS20050666A (en) 2007-12-31
CN1774418A (en) 2006-05-17
WO2004072025A2 (en) 2004-08-26
KR20050101215A (en) 2005-10-20
MY139102A (en) 2009-08-28

Similar Documents

Publication Publication Date Title
AR044496A1 (en) N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND ITS EMPLOYMENT AS MEDICATIONS
AR050603A1 (en) POLYCLINAL AMINES REPLACED WITH ARILO, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS MEDICATIONS
AR059458A1 (en) ARILDIHYDROISOQUINOLINONES REPLACED WITH AZACICLIL, PROCEDURE FOR PREPARATION AND USE AS MEDICATIONS
AR047453A1 (en) N - REPLACED CYCLHEXILIMIDAZOLINONES, PROCEDURES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS.
AR059522A1 (en) ARILDIHYDROISOQUINOLINAS REPLACED WITH AMINOALCOHOLES, PROCEDURE FOR ITS PREPARATION AND ITS USE AS MEDICATIONS
AR040514A1 (en) REPLACED DIARILIC HETEROCICLES, PROCEDURE FOR THE PREPARATION OF MEDICINES AND THE USE OF COMPOUNDS FOR SUCH PURPOSE
AR059521A1 (en) ARILTIENOPIRIMIDINAS REPLACED WITH AZACICLIL, PROCEDURE FOR PREPARATION AND USE AS A MEDICINAL PRODUCT
AR059520A1 (en) DERIVATIVES OF SUBSTITUTED AZACICLIL ARYLTIENOPIRIMIDINONES, PROCEDURE FOR PREPARATION, MEDICINES CONTAINING THERAPEUTIC USES AND MCH1R RECEIVER ANTAGONISTS.
AR072707A1 (en) HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
AR037534A1 (en) DERIVED FROM ADAMANTANO, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR USE IN THERAPY, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH COMPOUND AND SUCH COMPOSITION AND INTERMEDIATE COMPOUNDS
AR067757A1 (en) IMIDAZO DERIVATIVES [4,5-C] PIRIDIN-2-ONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME AS ANTIVIRAL AGENTS.
AR059956A1 (en) PHENETALONAMINE DERIVATIVES, PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR053652A1 (en) DERIVATIVES OF INDOL AS PROTEIN QUINASE INHIBITORS. PHARMACEUTICAL COMPOSITIONS
AR048023A1 (en) CETOAMIDS WITH P4 CYCLES AS INHIBITORS OF NS3 SERINA PROTEASA OF HEPATITIS C VIRUS
AR085987A1 (en) TRI- AND TETRACICLIC COMPOUNDS PIRAZOL [3,4-B] PIRIDINE AS ANTINEOPLASIC AGENTS
AR046711A1 (en) 5-7-DIAMINOPIRAZOLO [4,3D] PYRIMIDINS AS INHIBITORS OF THE PDE-5, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN THE TREATMENT OF HYPERTENSIONS
AR067931A1 (en) DERIVATIVES OF (PIRIDIN-3-IL-OXI) -PIRIDIN
AR068466A1 (en) CYANOISOQUINOLINE
ECSP066688A (en) CRYSTALLINE POLYMORPH OF A BISULPHATE SALT OF AZEPINOINDOL UNDERIVATES AS PHARMACEUTICAL AGENTS THROMBIN RECEPTOR ANTAGONIST
AR059429A1 (en) COMBINATIONS INVOLVING THE PROTES HCV INHIBITOR (S) AND TREATMENT METHODS RELATED TO THE SAME (S)
AR071763A1 (en) TRISUSTITUTED PIRAZOLS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USES OF THE SAME IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
AR054560A1 (en) SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AR035790A1 (en) PIRAZOLO DERIVATIVE COMPOUND [3,4-D] PYRIMIDINE AND METHOD TO PREPARE AN INTERMEDIATE COMPOUND
AR056199A1 (en) DERIVATIVES OF 8-OXOADENINE 9-SUBSTITUTED
AR064345A1 (en) 8-OXOADENINE DERIVATIVES

Legal Events

Date Code Title Description
FB Suspension of granting procedure